2022. VISIBLE 2

Phase 3/VDZ SC/ CD /Induct/Maintain

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Crohn's disease

Open label VDZ 300 mg IV induction therapy at weeks 0 and 2.
Clinically responders to induction in w6 were randomised to VDZ SC eow or placebo every 2 weeks.
Patients with moderately to severe active CD.

Primary endpoint: clinical remission (CDAI ≤150) at week 52.

Results:

- At w52, 48.0% of patients receiving vedolizumab SC versus 34.3% receiving placebo were in clinical remission [p = 0.008].
- At w52, 45.3% VDZ vs 18.2% placebo were in steroid free clinical remission.

Conclusion:
Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.



Vermeire S et al. J Crohns Colitis. 2002; 27-38